Astrazeneca (AZN) said Sunday its experimental drug, baxdrostat, intended to treat patients with resistant hypertension, met primary and secondary goals in a phase 3 trial.

The drugmaker said baxdrostat demonstrated a statistically significant and clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure compared with placebo at 12 weeks.

Baxdrostat also met key secondary endpoints, reducing ambulatory night-time and seated systolic blood pressure, and more patients achieved target blood pressure levels below 130 mmHg compared with placebo, the company said.

The company said the drug was generally well tolerated, with a safety profile consistent with earlier studies.

During the trial, patients received either 2 mg of baxdrostat or a placebo alongside standard therapy, with efficacy seen across the full 24-hour period, including early morning hours when cardiovascular risk is highest, it added.

Shares of the company were up 1.3% in Monday's premarket activity.